Results
Trial
Research Area
Duration
Locations
-
The purpose of this study is to see if cenicriviroc mesylate (or CVC) can reduce inflammation of the arteries (the…
Open and enrolling
HIV (and comorbidities)
24 weeks
Results
Trial
Research Area
Duration
Locations
The purpose of this study is to see if cenicriviroc mesylate (or CVC) can reduce inflammation of the arteries (the…
Open and enrolling
HIV (and comorbidities)
24 weeks
A5359: Long-Acting Antiretroviral Therapy in Non-adherent Persons Living with HIV (PLWH)
This four-step study compares Long-Acting (LA) Injectable Antiretroviral Therapy (ART) to standard of care (SOC) oral ART in previously non-adherent…
Open and enrolling
HIV (and comorbidities)
Steps 1-3 combined are a total of 128 weeks. Step 4 lasts 52 weeks.
Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses. Informed…
Open and enrolling
HIV (and comorbidities)
A5243: Non-US Genomic Sampling
Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing. This is a…
Open and enrolling
HIV (and comorbidities)
Weight gain after starting HIV therapy is common, but recent studies have found that some people with HIV (PWH) who…
Open and enrolling
HIV (and comorbidities)
Participants will be on study treatment for 48 weeks.
Since the early days of the HIV epidemic cytomegalovirus (CMV) has been one of the most common and devastating opportunistic…
Open and enrolling
HIV (and comorbidities)
About 2 years (96 weeks).